Dr. Joseph Mikhael, Chief Medical Officer at the International Myeloma Foundation, highlights an ASCO 2018 session about monoclonal antibodies used to treat multiple myeloma. Dr. Mikhael comments on the following:

  • The use of monoclonal antibodies are significant for myeloma patients at first relapse.

  • Monoclonal antibodies may be used in combination with lenalidomide, bortezomib, and other agents to help a patient reach remission.

  • Treatment with monoclonal antibodies must be individualized due to myeloma’s complexities.

In addition, Dr. Mikhael previews the use of new monoclonal antibodies and other new treatments, including CAR T-cell therapy.

 

 

 

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.